Stephen Harrow

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.8K citations

Open-label Trial, Radiation Therapy, Medicine +7

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

David A. Palma, Robert Olson, Stephen Harrow et al. · Journal of Clinical Oncology · 2020 · 1.2K citations · Full text

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

Stephen Harrow, Vakis Papanastassiou, J. Harland et al. · Gene Therapy · 2004 · 340 citations

Neuro-oncology, High-grade Glioma, Glioma +9

UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy

Gerard G. Hanna, Louise Murray, R. Patel et al. · Clinical Oncology · 2017 · 267 citations · Full text

Adaptive Radiotherapy, Radiation Medicine, Medical Imaging +8

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma, Robert Olson, Stephen Harrow et al. · BMC Cancer · 2019 · 250 citations · Full text